The rising tide of accident and emergency attendances is being driven by long-term health conditions rather than a lack of GP provision, concludes a study by Queen Mary University of London. More: A&E pressures not down to GP access, study
read moreUK companies Avacta and Glythera have sealed a licensing deal to develop drug conjugates using their combined technologies. More: Avacta, Glythera link to develop drug conjugates Source: News
read moreThe Scottish Medicines Consortium has rejected NHS funding for four new therapies, including Bristol-Myers Squibb and Roche’s respective cancer medicines Opdivo and Gazyvaro. More: SMC bars four medicines from NHS Source: News
read moreUS regulators have approved a supplemental New Drug Application for Boehringer Ingelheim’s lung cancer drug Gilotrif for first-line treatment of patients with metastatic non-small cell lung cancer whose tumours have non-resistant epidermal growth factor receptor. More: US expands scope of
read more© 1994 - 2026 B.M. Pharmaceuticals